Case Report: Rapid recurrence of psoriasiform dermatitis upon sequential anti-PD-1 therapy with pembrolizumab and tislelizumab with 3-year follow-up
Psoriasiform eruption is an uncommon cutaneous immune-related adverse event (irAE) associated with anti-PD-1 therapy, and its rapid recurrence upon switching to a different anti-PD-1 agent is a scarcely documented phenomenon. We report the case of a 59-year-old man with stage IIB lung adenocarcinoma...
Guardat en:
| Autors principals: | , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Frontiers Media S.A.
2026-03-01
|
| Col·lecció: | Frontiers in Immunology |
| Matèries: | |
| Accés en línia: | https://www.frontiersin.org/articles/10.3389/fimmu.2026.1760904/full |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|